Pennystocksupdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 09/02/2013 -- Biopharmaceutical company OPKO Health Inc (NYSE:OPK) said on Friday that its 3.0% convertible senior notes due 2033 are now convertible into shares of its common stock.
According to the company, the conversion right for the notes has been triggered because the product of its common stock closing price per share and the applicable conversion rate for the notes exceeded more than 98% the trading price for the notes.
The company stated the notes will continue to be convertible through 6 September 2013, and may be convertible thereafter, if one or more of the conversion conditions specified in the Indenture are satisfied.
Under the Indenture, a holder who elects to convert the notes will receive 141.4827 shares of the company's common stock per USD1,000 principal amount of notes.
With a recent loss of -1.05% to $8.49, the share price of Opko Health Inc. has moved forward from its 20 days moving average with 6.40% and remote positively from 50 days moving average with 11.72%.
What Should Investors Do With OPK Now? Find Out Here
Shares of Pfizer (NYSE:PFE) traded up 0.39% during mid-day trading on Monday, hitting $28.21. 29,782,348 shares of the company’s stock traded hands. Pfizer has a one year low of $23.55 and a one year high of $31.15.
The stock’s 50-day moving average is $28.86 and its 200-day moving average is $28.71. The company has a market cap of $186.8 billion and a P/E ratio of 7.80.
Pfizer last released its earnings data on Tuesday, July 30th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.01.
The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was down 7.1% on a year-over-year basis. Analysts expect that Pfizer will post $2.16 EPS for the current fiscal year.
Is PFE a Buy After Today’s News? Let’s Find Out Here
Neither Pennystocksupdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Pennystocksupdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. Pennystocksupdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Pennystocksupdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)